Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
Citations Over TimeTop 1% of 2015 papers
Abstract
The farnesoid X receptor (FXR) regulates bile acid, lipid and glucose metabolism. Here we show that treatment of mice with glycine-β-muricholic acid (Gly-MCA) inhibits FXR signalling exclusively in intestine, and improves metabolic parameters in mouse models of obesity. Gly-MCA is a selective high-affinity FXR inhibitor that can be administered orally and prevents, or reverses, high-fat diet-induced and genetic obesity, insulin resistance and hepatic steatosis in mice. The high-affinity FXR agonist GW4064 blocks Gly-MCA action in the gut, and intestine-specific Fxr-null mice are unresponsive to the beneficial effects of Gly-MCA. Mechanistically, the metabolic improvements with Gly-MCA depend on reduced biosynthesis of intestinal-derived ceramides, which directly compromise beige fat thermogenic function. Consequently, ceramide treatment reverses the action of Gly-MCA in high-fat diet-induced obese mice. We further show that FXR signalling in ileum biopsies of humans positively correlates with body mass index. These data suggest that Gly-MCA may be a candidate for the treatment of metabolic disorders.
Related Papers
- → Bile acid metabolism and signaling in liver disease and therapy(2017)288 cited
- → Bile Acid Metabolism and the Pathogenesis of Type 2 Diabetes(2011)236 cited
- → Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases(2017)51 cited
- → The relationship between bile acid concentration, glucagon-like-peptide 1, fibroblast growth factor 15 and bile acid receptors in rats during progression of glucose intolerance(2017)7 cited
- → Bile acid metabolism and type 2 diabetes(2014)